Under the collaboration, Epix has said, it is entitled to receive a $3 million milestone payment in the next 30 days.
In August, Epix announced that it had identified three lead candidates for the first discovery program, which entitled the company to a $3 million milestone payment. Using its proprietary, integrated computational-medicinal chemistry approach to drug discovery, Epix has identified these candidates.
Michael Kauffman, CEO of Epix, said: “We continue to be pleased by the ongoing progress of our collaboration with GlaxoSmithKline and our ability to move these discovery programs forward. Our ability to deliver lead candidates for two discovery programs further validates our approach and the productivity of our partnership with GSK. We look forward to continuing our efforts to deliver on our joint goals and achieve key milestones.”